Focus: Rezolute is a public-stage biotechnology company focused on biologic therapies, primarily in oncology and metabolic disorders. The company operates as a clinical-stage biotech with a lean pipeline in Phase 2–3 development.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Growing — net +7 jobs in 30d
8 jobs added vs 1 removed. Steady team buildout.
Rezolute is a high-risk, early-stage public biotech bet suitable only for candidates with high tolerance for execution risk and preference for early-stage impact over stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rezolute
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rezolute's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) The Globe and Mail
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? TradingView
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - Social Flow Trades - newser.com
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - Social Flow Trades newser.com
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - High Interest Stocks - newser.com
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - High Interest Stocks newser.com
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com - Investing.com UK
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com Investing.com UK
Congenital Hyperinsulinism Pipeline Gains Momentum with Novel - openPR.com
Congenital Hyperinsulinism Pipeline Gains Momentum with Novel openPR.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo